MPN stands for myeloproliferative neoplasm, a group of blood cancers in which the bone marrow produces too many of one or more types of blood cells. The three classic forms are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Each one involves a different overproduced cell type, but they share common genetic roots, overlapping symptoms, and the potential to progress into more serious disease over time.
Outside of medicine, MPN can also refer to the “Most Probable Number” technique used in microbiology to estimate bacteria in water and food samples. That meaning is covered briefly at the end of this article.
The Three Classic Types
All three classic MPNs are defined by overactive signaling in the bone marrow that drives excess cell production. What distinguishes them is which cell line dominates.
- Polycythemia vera (PV) produces too many red blood cells, thickening the blood and raising the risk of clots. Diagnosis requires a hemoglobin above 16.5 g/dL in men or 16.0 g/dL in women, along with characteristic bone marrow findings. PV occurs at a rate of roughly 1.2 new cases per 100,000 people per year in the United States.
- Essential thrombocythemia (ET) produces too many platelets. A platelet count at or above 450 × 10⁹/L is one of the major diagnostic criteria. Median survival is approximately 18 years overall, but younger patients can live 35 years or more after diagnosis. A risk model based on age and specific white blood cell counts separates patients into groups with median survivals ranging from 8 years (high risk) to 47 years (low risk).
- Primary myelofibrosis (PMF) involves scarring (fibrosis) of the bone marrow, which gradually impairs its ability to make normal blood cells. An early form called prefibrotic myelofibrosis can look similar to ET at first but carries a different prognosis and is now classified separately.
What Causes MPNs
Nearly all MPNs are driven by acquired genetic mutations, meaning they develop during a person’s lifetime rather than being inherited. The most common is a mutation in the JAK2 gene, which acts like a stuck “on” switch for a signaling pathway that tells the marrow to keep producing cells. Around 90% of PV patients carry this mutation. In ET, about half carry JAK2, while roughly a quarter have mutations in a gene called CALR. In primary myelofibrosis, JAK2 is found in about 57% of cases and CALR in another 15–30%.
A small percentage of patients, sometimes called “triple-negative,” carry none of the three main driver mutations (JAK2, CALR, or MPL). These cases can be harder to diagnose and often require additional genetic testing or close monitoring of bone marrow changes.
Common Symptoms
MPNs can be subtle for years. Many people are first flagged through a routine blood test showing abnormal counts before they notice anything wrong. When symptoms do appear, they tend to fall into a recognizable pattern. The standardized symptom tool used in clinical practice tracks ten core complaints: fatigue, difficulty concentrating, early fullness after eating, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers.
Fatigue is by far the most common and often the most disabling. Itching, particularly after a warm shower, is a hallmark of PV. Abdominal discomfort and early fullness typically come from an enlarged spleen, which swells as it works overtime to filter excess blood cells or takes over blood cell production when the marrow fails. As disease progresses, the spleen can become massively enlarged, and patients may develop worsening constitutional symptoms like drenching night sweats and unintentional weight loss.
How MPNs Are Diagnosed
Diagnosis relies on a combination of blood counts, genetic testing, and a bone marrow biopsy. No single test is enough on its own. Blood work identifies the abnormal counts, genetic testing looks for driver mutations like JAK2 or CALR, and the biopsy reveals the specific pattern of cell overgrowth and any scarring in the marrow. Bone marrow appearance remains the central feature that distinguishes one MPN from another, because blood counts alone can overlap between types.
For PV specifically, a low level of erythropoietin (the hormone that normally signals the body to make red blood cells) serves as a minor diagnostic criterion. Because the marrow is already overproducing on its own, the body’s natural signal gets suppressed.
Risks of Progression
One of the more concerning aspects of MPNs is their ability to transform over time. PV and ET can both progress to secondary myelofibrosis, in which the bone marrow becomes increasingly scarred. Any MPN can also transform into acute myeloid leukemia, a much more aggressive blood cancer. In a prospective study of patients with myelofibrosis initially classified as low risk, 5% developed leukemia and 10% died from disease progression during the observation period.
Blood clots are the other major threat. The excess cells make the blood thicker or stickier, raising the risk of strokes, heart attacks, deep vein thrombosis, and clots in unusual locations like the veins draining the liver or spleen. Managing clot risk is a central goal of treatment for all three classic MPNs.
Treatment Approaches
Treatment is tailored to the specific MPN type and the patient’s individual risk level. The goal for most people is not cure but rather controlling blood counts, reducing clot risk, managing symptoms, and slowing progression.
For polycythemia vera, the primary target is keeping the hematocrit (the percentage of blood volume occupied by red blood cells) below 45%. A landmark clinical trial demonstrated that maintaining this threshold significantly reduces the rate of blood clots. This is achieved through regular blood draws called phlebotomy, which work the same way as a blood donation to bring red cell levels down. When phlebotomy alone isn’t sufficient, medications that slow marrow production are added.
For myelofibrosis, drugs that block the overactive JAK-STAT signaling pathway have become the cornerstone of treatment since the first was approved in 2011. These medications don’t eliminate the disease, but they can substantially shrink an enlarged spleen and improve symptoms like night sweats, bone pain, and fatigue. In clinical trials, roughly a third of patients experienced at least a 35% reduction in spleen size within six months. For younger, higher-risk patients, a stem cell transplant remains the only potentially curative option, though it carries significant risks of its own.
Essential thrombocythemia treatment focuses on reducing clot risk through low-dose aspirin and, for higher-risk patients, medications that lower the platelet count.
MPN in Microbiology
In an entirely different context, MPN stands for Most Probable Number, a laboratory method for estimating bacterial concentrations in water, food, and soil. The technique works by diluting a sample into a series of broth cultures, then observing which dilutions still show bacterial growth. Using statistical tables, the number of positive and negative tubes at each dilution yields an estimate of the original bacterial population. Results typically take 24 to 48 hours. The method is widely used in water quality testing and food safety, particularly for detecting coliform bacteria as an indicator of fecal contamination.